Abstract:N6-methyladenosine (m6A) is the most abundant epigenetic modification of RNA, and its dysregulation drives aberrant transcription and translation programs that promote cancer occurrence and progression. Although defective gene regulation resulting from m6A often affects oncogenic and tumor-suppressing networks, m6A can also modulate tumor immunogenicity and immune cells involved in anti-tumor responses. Understanding this counterintuitive concept can aid the design of new drugs that target m6A to potentially improve the outcomes of cancer immunotherapies. Here, we provide an up-to-date and comprehensive overview of how m6A modifications intrinsically affect immune cells and how alterations in tumor cell m6A modifications extrinsically affect immune cell responses in the tumor microenvironment (TME). We also review strategies for modulating endogenous anti-tumor immunity and discuss the challenge of reshaping the TME. Strategies include: combining specific and efficient inhibitors against m6A regulators with immune checkpoint blockers; generating an effective programmable m6A gene-editing system that enables efficient manipulation of individual m6A sites; establishing an effective m6A modification system to enhance anti-tumor immune responses in T cells or natural killer cells; and using nanoparticles that specifically target tumor-associated macrophages (TAMs) to deliver messenger RNA or small interfering RNA of m6A-related molecules that repolarize TAMs, enabling them to remodel the TME. The goal of this review is to help the field understand how m6A modifications intrinsically and extrinsically shape immune responses in the TME so that better cancer immunotherapy can be designed and developed.

Dynamic M6a-Ncrnas Association and Their Impact on Cancer Pathogenesis, Immune Regulation and Therapeutic Response

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Overview of the interplay between m6A methylation modification and non-coding RNA and their impact on tumor cells

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

The Roles of M6a RNA Modifiers in Human Cancer

Interaction between N6-methyladenosine (m6A) modification and noncoding RNAs in cancer

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

The interaction between m6A modification and noncoding RNA in tumor microenvironment on cancer progression

N6-methyladenine modification in noncoding RNAs and its function in cancer

New understandings of the genetic regulatory relationship between non-coding RNAs and m6A modification

N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer

Role of N6-methyladenosine RNA modification in cancer

The interplay between m6A RNA methylation and noncoding RNA in cancer

Emerging roles of the crosstalk between non-coding RNAs and m<SUP>6</SUP>A modification in cancers

Novel insights into the interplay between m 6 A modification and noncoding RNAs in cancer

The Dual Role of N6‐methyladenosine Modification of RNAs is Involved in Human Cancers

The dual role of N6-methyladenosine modification of RNAs is involved in human cancers

The Roles of N6-methyladenosine and Its Target Regulatory Noncoding RNAs in Tumors: Classification, Mechanisms, and Potential Therapeutic Implications.

The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing

Targeting the RNA M6a Modification for Cancer Immunotherapy

Dual Effects of N6-methyladenosine on Cancer Progression and Immunotherapy